Clinical Trial Update: Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of R-ACVBP regimen with pegfilgrastim in high-risk, untreated CD20-positive diffuse large B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• R-ACVBP regimen with pegfilgrastim

Snippet

Sponsor: Lymphoma Study Association | Conditions: Untreated CD20-positive Large B-cell Lymphoma | Phase 2 | Status: COMPLETED